Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

278 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Giuliano M, Schettini F, Rognoni C, Milani M, Jerusalem G, Bachelot T, De Laurentiis M, Thomas G, De Placido P, Arpino G, De Placido S, Cristofanilli M, Giordano A, Puglisi F, Pistilli B, Prat A, Del Mastro L, Venturini S, Generali D. Giuliano M, et al. Among authors: jerusalem g. Lancet Oncol. 2019 Oct;20(10):1360-1369. doi: 10.1016/S1470-2045(19)30420-6. Epub 2019 Sep 4. Lancet Oncol. 2019. PMID: 31494037
An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer.
Capri G, Chang J, Chen SC, Conte P, Cwiertka K, Jerusalem G, Jiang Z, Johnston S, Kaufman B, Link J, Ro J, Schütte J, Oliva C, Parikh R, Preston A, Rosenlund J, Selzer M, Zembryki D, De Placido S. Capri G, et al. Among authors: jerusalem g. Ann Oncol. 2010 Mar;21(3):474-480. doi: 10.1093/annonc/mdp373. Epub 2009 Oct 8. Ann Oncol. 2010. PMID: 19815649 Free article. Clinical Trial.
["Triple negative" breast cancer].
Freres P, Collignon J, Gennigens C, Scagnol I, Rorive A, Barbeaux A, Coucke PA, Jérusalem G. Freres P, et al. Among authors: jerusalem g. Rev Med Liege. 2010 Mar;65(3):120-6. Rev Med Liege. 2010. PMID: 20411815 Free article. French.
Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.
Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, Verhoeven D, Pedrini JL, Smirnova I, Lichinitser MR, Pendergrass K, Garnett S, Lindemann JP, Sapunar F, Martin M. Di Leo A, et al. Among authors: jerusalem g. J Clin Oncol. 2010 Oct 20;28(30):4594-600. doi: 10.1200/JCO.2010.28.8415. Epub 2010 Sep 20. J Clin Oncol. 2010. PMID: 20855825 Clinical Trial.
mTOR inhibitors in advanced breast cancer: ready for prime time?
Martin LA, André F, Campone M, Bachelot T, Jerusalem G. Martin LA, et al. Among authors: jerusalem g. Cancer Treat Rev. 2013 Nov;39(7):742-52. doi: 10.1016/j.ctrv.2013.02.005. Epub 2013 Apr 1. Cancer Treat Rev. 2013. PMID: 23557794 Review.
Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study.
Awada A, Garcia AA, Chan S, Jerusalem GH, Coleman RE, Huizing MT, Mehdi A, O'Reilly SM, Hamm JT, Barrett-Lee PJ, Cocquyt V, Sideras K, Young DE, Zhao C, Chia YL, Hoch U, Hannah AL, Perez EA; NKTR-102 Study Group. Awada A, et al. Lancet Oncol. 2013 Nov;14(12):1216-25. doi: 10.1016/S1470-2045(13)70429-7. Epub 2013 Oct 4. Lancet Oncol. 2013. PMID: 24095299 Free article. Clinical Trial.
Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis.
Bachelot T, McCool R, Duffy S, Glanville J, Varley D, Fleetwood K, Zhang J, Jerusalem G. Bachelot T, et al. Among authors: jerusalem g. Breast Cancer Res Treat. 2014 Jan;143(1):125-33. doi: 10.1007/s10549-013-2778-5. Epub 2013 Nov 24. Breast Cancer Res Treat. 2014. PMID: 24272078 Free PMC article.
Disease management patterns for postmenopausal women in Europe with hormone-receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer.
André F, Neven P, Marinsek N, Zhang J, Baladi JF, Degun R, Benelli G, Saletan S, Jerusalem G. André F, et al. Among authors: jerusalem g. Curr Med Res Opin. 2014 Jun;30(6):1007-16. doi: 10.1185/03007995.2014.887002. Epub 2014 Feb 3. Curr Med Res Opin. 2014. PMID: 24490834 Free article.
European inter-institutional impact study of MammaPrint.
Cusumano PG, Generali D, Ciruelos E, Manso L, Ghanem I, Lifrange E, Jerusalem G, Klaase J, de Snoo F, Stork-Sloots L, Dekker-Vroling L, Lutke Holzik M. Cusumano PG, et al. Among authors: jerusalem g. Breast. 2014 Aug;23(4):423-8. doi: 10.1016/j.breast.2014.02.011. Epub 2014 Mar 28. Breast. 2014. PMID: 24685596 Free article.
278 results